Page 1 | Search Results | Hematology, ASH Education Program

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Novel alternate hemostatic agents for patients with inhibitors: beyond bypass therapy

Margaret V. Ragni

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 605–609.

https://doi.org/10.1182/asheducation-2017.1.605

Published: 2017

Journal Articles

Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches

Shannon L. Meeks, Glaivy Batsuli

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 657–662.

https://doi.org/10.1182/asheducation-2016.1.657

Published: 2016

Journal Articles

Coagulopathy in liver disease: a balancing act

Jody L. Kujovich

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 243–249.

https://doi.org/10.1182/asheducation-2015.1.243

Published: 2015

Journal Articles

Lasting power of new clotting proteins

Jerry S. Powell

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 355–363.

https://doi.org/10.1182/asheducation-2014.1.355

Published: 2014

Journal Articles

Toward optimal therapy for inhibitors in hemophilia

Christine L. Kempton, Shannon L. Meeks

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 364–371.

https://doi.org/10.1182/asheducation-2014.1.364

Published: 2014

Journal Articles

The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders

Margaret V. Ragni

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 44–51.

https://doi.org/10.1182/asheducation-2013.1.44

Published: 2013

Journal Articles

Pharmacologic tools to reduce bleeding in surgery

Sam Schulman

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 517–521.

https://doi.org/10.1182/asheducation.V2012.1.517.3798536

Published: 2012

Journal Articles

Therapeutic challenges in acquired factor VIII deficiency

Peter W. Collins

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 369–374.

https://doi.org/10.1182/asheducation.V2012.1.369.3798356

Published: 2012

Journal Articles

Alternative Strategies for Gene Therapy of Hemophilia

Robert R. Montgomery, Qizhen Shi

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 197–202.

https://doi.org/10.1182/asheducation-2010.1.197

Published: 2010

Journal Articles

Recombinant Factor VIIa: An Assessment of Evidence Regarding Its Efficacy and Safety in the Off-Label Setting

Aaron C. Logan, Lawrence T. Goodnough

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 153–159.

https://doi.org/10.1182/asheducation-2010.1.153

Published: 2010

Journal Articles

What Is the Evidence for the Off-label Use of Recombinant Factor VIIa (rFVIIa) in the Acute Reversal of Warfarin?

Rachel P. Rosovsky, Mark A. Crowther

Hematology Am Soc Hematol Educ Program (2008) 2008 (1): 36–38.

https://doi.org/10.1182/asheducation-2008.1.36

Published: 2008

Journal Articles

Challenges in the Therapeutic Use of a “So-Called” Universal Hemostatic Agent: Recombinant Factor VIIa

W. Keith Hoots

Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 426–431.

https://doi.org/10.1182/asheducation-2006.1.426

Published: 2006

Journal Articles

New Perspectives in Hemophilia Treatment

Craig M. Kessler

Hematology Am Soc Hematol Educ Program (2005) 2005 (1): 429–435.

https://doi.org/10.1182/asheducation-2005.1.429

Published: 2005

Journal Articles

Transfusion Medicine: Joint ASH and AABB Educational Session

Lawrence T. Goodnough, Patricia E. Hewitt, Christopher C. Silliman

Hematology Am Soc Hematol Educ Program (2004) 2004 (1): 457–472.

https://doi.org/10.1182/asheducation-2004.1.457

Published: 2004

Journal Articles

Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia

Ulla Hedner, David Ginsburg, Jeanne M. Lusher, Katherine A. High

Hematology Am Soc Hematol Educ Program (2000) 2000 (1): 241–265.

https://doi.org/10.1182/asheducation.V2000.1.241.241

Published: 2000

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Novel alternate hemostatic agents for patients with inhibitors: beyond bypass therapy

Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches

Coagulopathy in liver disease: a balancing act

Lasting power of new clotting proteins

Toward optimal therapy for inhibitors in hemophilia

The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders

Pharmacologic tools to reduce bleeding in surgery

Therapeutic challenges in acquired factor VIII deficiency

Alternative Strategies for Gene Therapy of Hemophilia

Recombinant Factor VIIa: An Assessment of Evidence Regarding Its Efficacy and Safety in the Off-Label Setting

What Is the Evidence for the Off-label Use of Recombinant Factor VIIa (rFVIIa) in the Acute Reversal of Warfarin?

Challenges in the Therapeutic Use of a “So-Called” Universal Hemostatic Agent: Recombinant Factor VIIa

New Perspectives in Hemophilia Treatment

Transfusion Medicine: Joint ASH and AABB Educational Session

Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia

ASH Publications

American Society of Hematology